| 09:30 – 09:45
|| Registration and coffee/tea/pastries
| 09:45 – 09:50
|| Introduction and welcome
|| Session 1: Implementation of Phase I model-based adaptive designs (Chair: Dr Graham Wheeler, UCL)
| 09:50– 10:30
||Life Journey of a Continual Reassessment Method Trial: Design, Conduct and Reporting
Speaker: Dr Christina Yap, Reader in Biostatistics and Clinical Trials, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
I will recount the challenges, heartaches, lessons learnt, and the joys of developing and implementing my first CRM trial, VIOLA, from initial conception to final publication (Yap et al 2017, Craddock et al 2019). Would I do it again?
| 10:30 – 11:00
||CRMs from a clinician perspective: Continual Reassessment or Continual Stress
Speaker: Dr Graham Collins, Haematology consultant and lymphoma lead, Oxford University Hospitals
How statisticians and clinicians approach CRM models can be very different. This talk seeks to explain a clinician perspective - the benefits the model can give in enabling a swifter and more efficient design, but also the possible added stresses. I will mainly use the RomiCar trial as the basis for discussion. The aim is to foster understanding between clinicians and statisticians in order to enable better team working.
| 11:00 – 11:20
|| Refreshment Break
|| Session 2: Early Phase Multi-arm (Platform) Designs in Action (Chair: Professor Christopher Weir, University of Edinburgh)
| 11:20 – 11:30
||An introduction to basket, umbrella and platform designs and how statistics can help
Speaker: Professor Cindy Billingham, Professor of Biostatistics, CRCTU, University of Birmingham
| 11:30 - 12:00
||Precision Panc: The next generation therapeutic development platform for pancreatic cancer
Speaker: Dr David Chang, Reader and Honorary Consultant Pancreatic Surgeon, University of Glasgow
Precision-Panc is a therapeutic development platform for pancreatic cancer, that brings in the continuous forward and backward learning of “discovery”, “preclinical” and “clinical” development. The principle of Precision-Panc will be presented with examples of translating deep science discovery into novel clinical trial design.
| 12:00 – 12:20
Practical challenges of delivering a platform trial from a trial management perspective Speaker: Ms Claire Snowdon, Deputy Director & Operations Director, ICR Clinical Trials & Statistics Unit, The Institute of Cancer Research
I will focus on the logistical challenges of delivering a single protocol screening platform with multiple incorporated treatment cohorts, with particular reference to financial, resource and regulatory aspects, using plasmaMATCH as an example in my talk.
The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic CHoices (plasmaMATCH) Trial:
A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening.
| 12:20 – 12:40
|| Discussion with the panel: Cindy, David and Claire
| 12:40 – 13:40
Session 3: Regulatory Perspectives (Chair: Dr Christina Yap, CRCTU, University of Birmingham)
| 13:40 – 14:40
||Regulatory perspective of early phase I/II designs, including basket, umbrella and platform designs
Speaker: Dr Khadija Rantell, Statistical Assessor, Medicines and Health Care Products Regulatory Agency (MHRA)
Within the EU regulatory system, scientific advice is available to support the qualification of innovative development methods for specific intended use in the context of research and development into pharmaceuticals. MHRA supports innovative trial designs (adaptive trials, basket, umbrella, and platform designs) by engaging with sponsors to assist with innovative protocol designs and facilitating efficient approval and amendment to such trials.
The MHRA are members of the Modelling and Simulation Working party (MSWP) at the EMA who assess modelling methodology and support innovation in areas like first-in-man or dose finding trials. The MHRA also collaborate with other organisations to promote best methodologies in the set up and delivery of innovative trials. Based on MHRA’s experience in early phase trials, this talk will highlight current trends in dose-finding methodology, and it will also discuss the key challenges with master protocols (e.g. lack of common terminology) and the statistical considerations with such trials, e.g. independence of sub-studies, shared control groups, and pooling of data across sub-studies.
| 14:40 – 15:10
||Research team and PPI perspectives on Early Phase Trials Designs
Speakers: Mrs Aimee Jackson, Senior Biostatistician and Dr Christina Yap, Reader in Biostatistics and Clinical Trials, CRCTU, University of Birmingham
| 15:10 – 15:50
||Update on past activities. Identify future training courses/projects.
Speaker: Dr Simon Bond, Senior Statistician, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust
A key output from the group is the recently published paper ‘How to design a dose-finding study using the continual reassessment method’, which will be introduced and then we will discuss and plan how to ensure the paper is communicated widely and effectively in the clinical trials community. Future objectives emerging from the day’s talks and workshops will be agreed.
| 15:50 – 16:00
Speakers: Drs Simon Bond and Christina Yap